Immunosuppression decreases inflammation and increases AAV6-hSERCA2a- mediated SERCA2a expression

Human Gene Therapy

Volumn 23, Issue 7, 2012, Pages 722-732

  Zhu, Xiaodong ^a   McTiernan, Charles F ^a   Rajagopalan, Navin ^a   Shah, Hemal ^a   Fischer, David ^a   Toyoda, Yoshiya ^a   Letts, Dustin ^a   Bortinger, Jonathan ^a   Gibson, Gregory ^a   Xiang, Wenyu ^a   McCurry, Kenneth ^a   Mathier, Michael ^a   Glorioso, Joseph C ^b   London, Barry ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANINE ADENOVIRUS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; HEART FAILURE; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PROTEIN EXPRESSION; SYSTOLE; TACHYCARDIA; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; DEPENDOVIRUS; DNA, VIRAL; DOGS; EPITOPES; GENETIC THERAPY; GENETIC VECTORS; GENOME, VIRAL; HEART FAILURE; HEART VENTRICLES; HUMANS; IMMUNOSUPPRESSION; MYOCARDITIS; RABBITS; RECOMBINANT PROTEINS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

ADENO-ASSOCIATED VIRUS; CANIS FAMILIARIS;

EID: 84864375254     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.108     Document Type: Article

References (48)

1. American Heart Association. (2009). Heart Disease and Stroke Statistics-2009 Update. (American Heart Association, Dallas, TX).
2. 2+ transport. Circ. Res. 93, 487-490. (Pubitemid 37163227)
3. Bish, L.T., Sleeper, M.M., Brainard, B., et al. (2008). Percutaneous transendocardial delivery of self-complementary adenoassociated virus 6 achieves global cardiac gene transfer in canines. Mol. Ther. 16, 1953-1959.
4. Brantly, M.L., Chulay, J.D., Wang, L., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 16363-16368.
5. Braz, J.C., Gregory, K., Pathak, A., et al. (2004). PKC-a regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10, 248-254. (Pubitemid 38667614)
6. 2+-ATPases are on opposite sides of the membrane. J. Biol. Chem. 267, 9321-9325.
7. Davidoff, A.J., and Gwathmey, J.K. (1994). Pathophysiology of cardiomyopathies. I. Animal models and humans. Curr. Opin. Cardiol. 9, 369-378.
8. Daya, S., and Berns, K.I. (2008). Gene therapy using adenoassociated virus vectors. Clin. Microbiol. Rev. 21, 583-593.
9. 2+-ATPase in a rat model of heart failure. Circulation 104, 1424-1429. (Pubitemid 32880157)
10. Del Monte, F., Dalal, R., Tabchy, A., et al. (2004). Transcriptional changes following restoration of SERCA2a levels in failing rat hearts. FASEB J. 18, 1474-1476. (Pubitemid 39561619)
11. Gianni, D., Chan, J., Gwathmey, J.K., et al. (2005). SERCA2a in heart failure: Role and therapeutic prospects. J. Bioenerg. Biomembr. 37, 375-380. (Pubitemid 43725161)
12. Gregorevic, P., Schultz, B.R., Allen, J.M., et al. (2009). Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol. Ther. 17, 1427-1433.
13. Hajjar, R.J., Schmidt, U., Matsui, T., et al. (1998). Modulation of ventricular function through gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 95, 5251-5256. (Pubitemid 28208584)
14. Hajjar, R.J., Zsebo, K., Deckelbaum, L., et al. (2008). Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J. Card. Fail. 14, 355-367. (Pubitemid 351756538)
15. Herzog, R.W., Mount, J.D., Arruda, V.R., et al. (2001). Muscledirected gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol. Ther. 4, 192-200.
16. Herzog, R.W., Fields, P.A., Arruda, V.R., et al. (2002). Hum. Gene Ther. 13, 1281-1291.
17. Hunt, S.A., Baker, D.W., Chin, M.H., et al. (2001). ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Available at www.acc.org/clinical/guidelines/ failure/hf-index.htm (accessed April 19, 2012).
18. Isa, A., Kasprowicz, V., Norbeck, O., et al. (2005). Prolonged activation of virus-specific CD8+ T cells after acute B19 infection. PLoS Med. 2, e343.
19. Jaski, B.E., Jessup, M.L., Mancini, D.M., et al.; Cardiac Disease (CUPID) Trial Investigators. (2009). Calcium up-regulation by percutaneous administration of gene therapy. J. Card. Fail. 15, 171-181.
20. Jessup, M., Greenberg, B., Mancini, D., et al.; Cardiac Disease (CUPID) Investigators. (2011). Calcium upregulation by percutaneous administration of gene therapy. Circulation 124, 304-313.
21. Jiang, H., Couto, L.B., Patarroyo-White, S., et al. (2006). Effects of transient immunosuppression on adenoassociated, virusmediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108, 3321-3328.
22. Kaplitt, M.G., Xiao, X., Samulski, R.J., et al. (1996). Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann. Thorac. Surg. 62, 1669-1676. (Pubitemid 26421099)
23. Kawase, Y., Ly, H.Q., Prunier, F., et al. (2008). Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119. (Pubitemid 351374774)
24. Kim, T.S., Hufford, M.M., Sun, J., et al. (2010). Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J. Exp. Med. 207, 1161-1172.
25. Lö ser, P., Jennings, G.S., Strauss, M., and Sandig, V. (1998). Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: Involvement of NFjB. J. Virol. 72, 180-190. (Pubitemid 28048827)
26. Manno, C.S., Pierce, G.F., Arruda, V.R., et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347. (Pubitemid 43355084)
27. McTiernan, C.F., Mathier, M.A., Zhu, X., et al. (2007). Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther. 14, 1613-1622. (Pubitemid 350143187)
28. Mingozzi, F., and High, K.A. (2007). Immune responses to AAV in clinical trials. Curr. Gene Ther. 7, 316-324. (Pubitemid 47595774)
29. Mingozzi, F., Maus, M.V., Hui, D.J., et al. (2007). CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422. (Pubitemid 46559826)
30. Nguyen, D.Q., and Thourani, V.H. (2010). Third-generation continuous flow left ventricular assist devices. Innovations 5, 250-258
31. Niemeyer, G.P., Herzog, R.W., Mount, J., et al. (2009). Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113, 797-806.
32. Nikolaidis, L.A., Mathier, M.A., Doverspike, A., et al. (2005). Coronary blood flow responses are impaired independent of NO and endothelial function in conscious dogs with dilated cardiomyopathy. J. Card. Fail. 11, 313-321. (Pubitemid 40616902)
33. Ohshima, S., Shin, J., Yuasa, K., et al. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther. 17, 73-80.
34. Pien, G.C., Basner-Tschakarjan, E., Hui, D.J., et al. (2009). Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J. Clin. Invest. 119, 1688-1695.
35. Raake, P.W., Hinkel, R., Muller, S., et al. (2008). Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther. 15, 12-17. (Pubitemid 350284205)
36. Rimmelzwaan, G.F., Groen, J., Egberink, H., et al. (1991). The use of enzyme-linked immunosorbent assay systems for serology and antigen detection in parvovirus, coronavirus and rotavirus infections in dogs. Vet. Microbiol. 26, 25-40.
37. Stieger, K., Schroeder, J., Provost, N., et al. (2009). Detection of intact rAAV particles up to 6 years after successful gene transfer in the retina of dogs and primates. Mol. Ther. 17, 516-523.
38. Turner, D.L., Cauley, L.S., Khanna, K.M., and Lefrançois, L. (2007). Persistent antigen presentation after acute vesicular stomatitis virus infection. J. Virol. 81, 2039-2046. (Pubitemid 46214475)
39. Vardeny, O., Sweitzer, N.K., Detry, M.A., et al. (2009). Decreased immune responses to influenza vaccination in patients with heart failure. J. Card. Fail. 15, 368-373.
40. Wang, L., Cao, O., Swalm, B., et al. (2005). Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther. 12, 1453-1464. (Pubitemid 41486134)
41. Wang, Z., Allen, J.M., Riddell, S.R., et al. (2007a). Immunity to adeno-associated virus-mediated gene transfer in a randombred canine model of duchenne muscular dystrophy. Hum. Gene Ther. 18, 18-26. (Pubitemid 46105461)
42. Wang, Z., Kuhr, C.S., Allen, J.M., et al. (2007b). Sustained AAVmediated dystrophin expression in a canine model of duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 15, 1160-1166. (Pubitemid 46813619)
43. Wang, Z., Storb, R., Lee, D., et al. (2010). Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol. Ther. 18, 617-624.
44. Young, J.B., Abraham, W.E., Smith, A.L., et al.; Multicenter In-Sync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. (2003). Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 289, 2719-2721.
45. Yuasa, K., Yoshimura, M., Urasawa, N., et al. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther. 14, 1249-1260. (Pubitemid 47299950)
46. Yue, Y., Ghosh, A., Long, C., et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther. 16, 1944-1952.
47. Xiao, X., Li, J., and Samulski, R.J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098-8108. (Pubitemid 26339120)
48. Xiao, X., Li, J., and Samulski, R.J. (1997). Role for highly regulated rep gene expression in adeno-associated virus vector production. J. Virol. 71, 5236-5243. (Pubitemid 27258196)